Crystal form of capsid protein assembly inhibitor containing N-hetero five-membered ring and its application
By providing a N-mixed five-membered ring capsid protein assembly inhibitor and its crystal form, the problem of cccDNA removal difficulties in existing treatment plans is solved, and effective inhibition of hepatitis B virus is achieved and improved The therapeutic effect.
Patent Information
- Application Number
- CN202080066509.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-09-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2040-09-28
AI Technical Summary
The existing treatment options for chronic viral hepatitis B cannot effectively remove cccDNA in the repository, resulting in a low cure rate and a lack of effective targets for capsid protein assembly.
A compound of formula I containing a capsid protein assembly inhibitor containing an N-mixed five-membered ring is provided and its crystal forms are used to prepare drugs for preventing or treating hepatitis B virus infection, affecting viral replication by blocking the capsid protein assembly process. .
This compound has good pharmacological activity and stability, can effectively inhibit the replication of HBV, and provides a new potential method for the treatment of hepatitis B, especially by blocking the capsid protein assembly process, which significantly improves the effectiveness of the treatment.
Smart Images

Figure CN114430736B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority and benefits of Chinese Patent Application No. 201910934549.0 filed with the State Intellectual Property Office of China on September 29, 2019, and the contents disclosed in said application are incorporated herein by reference in their entirety. Technical Field
[0003] The present application relates to a capsid protein assembly inhibitor crystalline form containing an N-hetero five-membered ring, specifically to a crystalline form of a compound of formula I, and also includes the use of the crystalline form in the preparation of drugs for preventing or treating diseases that benefit from capsid protein assembly inhibition. Background Art
[0004] Currently, chronic hepatitis B cannot be cured but can only be controlled, and is currently limited to two types of agents (interferon and nucleoside analogs / inhibitors of viral polymerase). The low cure rate of HBV is partly due to the presence and persistence of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes. Current treatment options cannot eliminate cccDNA in the reservoir, and some new targets for HBV such as core inhibitors (Core inhibitors, such as viral capsid protein formation or assembly inhibitors and cccDNA inhibitors and interferon-stimulated gene activators, etc.) are expected to bring hope for curing hepatitis B (Mayur Brahmania, et al. New therapeutic agents for chronic hepatitis B). The HBV capsid is assembled by core proteins. Before reverse transcription, HBV reverse transcriptase and pgRNA need to be properly wrapped by capsid proteins. Therefore, blocking capsid protein assembly or accelerating capsid protein degradation will block the capsid protein assembly process, thereby affecting viral replication. SUMMARY OF THE INVENTION
[0006] In one aspect, the present application provides a crystal of a compound of formula I,
[0007]
[0008] On the other hand, the present application provides a crystalline composition, wherein the crystals of the compound of formula I described in the present application account for more than 50% of the weight of the crystalline composition, preferably more than 80%, more preferably more than 90%, and most preferably more than 95%.
[0009] In yet another aspect, the present application provides a pharmaceutical composition comprising a therapeutically effective amount of a crystal of the compound of formula I described in the present application, or a crystalline composition thereof.
[0010] On the other hand, the present application also provides the use of the crystal of the compound of formula I described in the present application, its crystalline composition, or its pharmaceutical composition in the preparation of drugs for preventing or treating diseases that benefit from the inhibition of capsid protein assembly.
[0011] On the other hand, the present application also provides the use of the crystal of the compound of formula I described in the present application, its crystal composition, or its pharmaceutical composition in the preparation of a drug for preventing or treating hepatitis B virus infection.
[0012] On the other hand, the present application also provides the use of the crystal of the compound of formula I described in the present application, its crystalline composition, or its pharmaceutical composition in preventing or treating diseases that benefit from the inhibition of capsid protein assembly.
[0013] On the other hand, the present application also provides a method for preventing or treating a disease that benefits from the inhibition of capsid protein assembly, comprising administering a therapeutically effective amount of a crystal of the compound of formula I described in the present application, a crystalline composition thereof, or a pharmaceutical composition thereof to a mammal in need of such prevention or treatment.
[0014] On the other hand, the present application also provides crystals of the compound of formula I described in the present application, crystal compositions thereof, or pharmaceutical compositions thereof for preventing or treating diseases that benefit from the inhibition of capsid protein assembly. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is the XRPD spectrum of Type I crystal of the compound of formula I.
[0016] Figure 2 This is the DSC spectrum of Type I crystals of the compound of formula I.
[0017] Figure 3 It is the XRPD spectrum of Type II crystal of the compound of formula I.
[0018] Figure 4 It is the DSC spectrum of type II crystal of the compound of formula I. DETAILED DESCRIPTION OF THE INVENTION
[0020] In one aspect, the present application provides a crystal of a compound of formula I,
[0021]
[0022] On the other hand, the present application provides a type I crystal of the compound of formula I, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 16.47±0.20°, 18.11±0.20°, 24.48±0.20° and 26.79±0.20°; in some schemes of the present application, the X-ray powder diffraction pattern of the type I crystal has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 12.72±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 19.79±0.20°, 24.48±0.20° and 26.79±0.20°; the present application In some embodiments of the present application, the X-ray powder diffraction pattern of the above-mentioned type I crystal has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 10.44±0.20°, 12.72±0.20°, 15.06±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 19.79±0.20°, 20.46±0.20°, 24.48±0.20°, 26.79±0.20°, and 31.46±0.20°; In some embodiments of the present application, the X-ray powder diffraction pattern of the above-mentioned type I crystal has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 9.68±0.20°, 1 0.44±0.20°, 12.72±0.20°, 15.06±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 19.79±0.20°, 20.46±0.20°, 24.48±0.20°, 26.02±0.20°, 26.79±0.20°, 27.67±0.20° and 31.46±0.20°; in some embodiments of the present application, the X-ray powder diffraction pattern of the above-mentioned type I crystal has characteristic diffraction peaks at the following 2θ angles: 4.86±0.20°, 9.21±0.20°, 9.68±0.20°, 10.44±0.20°, 12.47±0.20°, 13. ±0.20°, 12.72±0.20°, 15.06±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 18.74±0.20°, 19.19±0.20°, 19.79±0.20°, 20.46±0.20°, 20.94±0. 20°, 21.65±0.20°, 21.96±0.20°, 23.12±0.20°, 24.48±0.20°, 26.02±0.20°, 26.79±0.20°, 27.67±0.20°, 29.36±0.20°, 31.46±0.20° and 34.17±0.20°.
[0023] In some embodiments of the present application, in the XRPD spectrum of the above-mentioned type I crystal, the peak position and relative intensity of the diffraction peak are shown in the following Table 1:
[0024] Table 1 XRPD data of type I crystals
[0025]
[0026] In some embodiments of the present application, the X-ray powder diffraction (XRPD) pattern of the above-mentioned type I crystal is as follows: Figure 1 shown.
[0027] In some embodiments of the present application, the differential scanning calorimetry (DSC) curve of the above-mentioned type I crystal has an endothermic peak at 231.26±5°C.
[0028] In some embodiments of the present application, the DSC spectrum of the above-mentioned type I crystal is as follows: Figure 2 shown.
[0029] In another aspect, the present application provides a method for preparing type I crystals, the method comprising the following steps:
[0030] The above compound of formula I is added to a solvent, and then the solid is isolated.
[0031] In some embodiments of the present application, the method for preparing type I crystals comprises the following steps: adding the compound of formula I described above to a solvent, crystallizing, and then separating the solid.
[0032] In some embodiments of the present application, the method for preparing the above-mentioned type I crystal, wherein the solvent is selected from a mixture of one or more of methanol, acetonitrile or water. In some embodiments of the present application, the method for preparing the above-mentioned type I crystal, wherein the solvent is selected from a mixture of methanol, or acetonitrile and water.
[0033] In some schemes of the present application, in the method for preparing the above-mentioned type I crystal, the volume mass ratio of the solvent to the compound of formula I is 1 to 100 ml / g; in some embodiments of the present application, the volume mass ratio of the solvent to the compound of formula I is 1 ml / g, 5 ml / g, 10 ml / g, 15 ml / g, 20 ml / g, 25 ml / g, 30 ml / g, 35 ml / g, 40 ml / g, 45 ml / g, 50 ml / g, 55 ml / g, 60 ml / g, 65 ml / g, 70 ml / g, 75 ml / g, 80 ml / g, 85 ml / g, 90 ml / g, 100 ml / g or a range formed by any proportion.
[0034] In some schemes of the present application, in the preparation method of the above-mentioned type I crystal, the volume mass ratio of methanol to the compound of formula I is 1-20 ml / g; in some embodiments of the present application, the volume mass ratio of methanol to the compound of formula I is 1 ml / g, 2 ml / g, 3 ml / g, 4 ml / g, 5 ml / g, 6 ml / g, 7 ml / g, 8 ml / g, 9 ml / g, 10 ml / g, 11 ml / g, 12 ml / g, 13 ml / g, 14 ml / g, 15 ml / g, 16 ml / g, 17 ml / g, 18 ml / g, 19 ml / g, 20 ml / g or a range formed by any proportion; in some embodiments of the present application, the volume mass ratio of methanol to the compound of formula I is 1-10 ml / g or 2-8 ml / g; in some embodiments of the present application, the volume mass ratio of methanol to the compound of formula I is 5 ml / g.
[0035] In some schemes of the present application, in the preparation method of the above-mentioned type I crystal, the volume mass ratio of acetonitrile to the compound of formula I is 1-20 ml / g; in some embodiments of the present application, the volume mass ratio of acetonitrile to the compound of formula I is 1 ml / g, 2 ml / g, 3 ml / g, 4 ml / g, 5 ml / g, 6 ml / g, 7 ml / g, 8 ml / g, 9 ml / g, 10 ml / g, 11 ml / g, 12 ml / g, 13 ml / g, 14 ml / g, 15 ml / g, 16 ml / g, 17 ml / g, 18 ml / g, 19 ml / g, 20 ml / g or a range formed by any proportion; in some embodiments of the present application, the volume mass ratio of acetonitrile to the compound of formula I is 5-18 ml / g or 8-16 ml / g; in some embodiments of the present application, the volume mass ratio of acetonitrile to the compound of formula I is 12.5 ml / g.
[0036] In some schemes of the present application, in the preparation method of the above-mentioned Type I crystal, the volume ratio of acetonitrile to water is 1:1 to 1:10; in some embodiments of the present application, the volume ratio of acetonitrile to water is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or a range formed by any ratio; in some embodiments of the present application, the volume ratio of acetonitrile to water is 1:1 to 1:5; in some embodiments of the present application, the volume ratio of acetonitrile to water is 1:5.
[0037] In some embodiments of the present application, in the method for preparing the above-mentioned type I crystal, the method for separating the solid is selected from filtration.
[0038] In some embodiments of the present application, the method for preparing the above-mentioned type I crystal comprises the following steps: adding the above-mentioned compound of formula I to a solvent, stirring to dissolve, and optionally heating the solution to dissolve.
[0039] In some embodiments of the present application, the method for preparing the above-mentioned type I crystal optionally includes a process of cooling to room temperature and / or cooling and crystallizing in an ice-water bath, and / or optionally adding water to allow crystallization.
[0040] On the other hand, the present application also provides type II crystals of the compound of formula I, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 14.09±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20° and 22.91±0.2°; in some schemes of the present application, the X-ray powder diffraction pattern of the type II crystals has characteristic diffraction peaks at the following 2θ angles: 8.45±0.20°, 13.35±0.20°, 14.09±0.20°, 14.90±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20°, 19.64±0.20° and 22.91±0.2°; in some schemes of the present application, the X-ray powder diffraction pattern of the above-mentioned type II crystal has characteristic diffraction peaks at the following 2θ angles: 8.45±0.20°, 11.15±0.20°, 13.35±0.20°, 14.09±0.20°, 14.90±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20°, 19.64±0.20°, 20.97±0.20°, 22.91±0.2°, 23.68±0.20°, and 25.24±0.2°; in some schemes of the present application, the X-ray powder diffraction pattern of the above-mentioned type II crystal has characteristic diffraction peaks at the following 2θ angles Characteristic diffraction peaks: 8.45±0.20°, 11.15±0.20°, 13.35±0.20°, 14.09±0.20°, 14.90±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20°, 19.64±0.20°, 20.25±0.20°, 20.97±0.20°, 21.42±0.20°, 22.91±0.2°, 23.68±0.20°, 25.24±0.2°, 27.72±0.2° and 30.00±0.2°; In some embodiments of the present application, the X-ray powder diffraction pattern of the above-mentioned type II crystal has characteristic diffraction peaks at the following 2θ angles :4.74±0.20°、7.94±0.20°、8.45±0.20°、9.40±0.20°、9.91±0.20°、11.15±0.20°、13.35±0.20°、14.09±0.20°、14.90±0.20°、15.81±0.20°、17.40± 0.20°, 18.81±0.20°, 19.64±0.20°, 20.25±0.20°, 20.97±0.20°, 21.42±0.20°, 22.91±0.2°, 23.68±0.20°, 25.24±0.2°, 27.72±0.2°, and 30.00±0.2°.
[0041] In some embodiments of the present application, in the XRPD spectrum of the above-mentioned type II crystal, the peak position and relative intensity of the diffraction peak are shown in Table 2 below:
[0042] Table 2 XRPD data of type II crystals
[0043]
[0044] In some embodiments of the present application, the X-ray powder diffraction (XRPD) pattern of the above-mentioned type II crystal is as follows: Figure 3 shown.
[0045] In some embodiments of the present application, the differential scanning calorimetry (DSC) curve of the above-mentioned type II crystal has an endothermic peak at 225.05±5°C.
[0046] In some embodiments of the present application, the DSC spectrum of the above-mentioned type II crystal is as follows: Figure 4 shown.
[0047] In another aspect, the present application provides a method for preparing the above-mentioned Type II crystal, which comprises the following steps: adding the compound of formula I to a solvent, and then precipitating a solid.
[0048] In some embodiments, the method for preparing the above-mentioned Type II crystal, wherein the solvent is selected from a mixture of one or more of acetone, tetrahydrofuran or water. In some embodiments, the method for preparing the above-mentioned Type II crystal, wherein the solvent is selected from a mixture of acetone and water, or a mixture of tetrahydrofuran and water.
[0049] In some schemes of the present application, in the method for preparing the above-mentioned Type II crystal, the volume mass ratio of the solvent to the compound of formula I is 1 to 100 ml / g; in some embodiments of the present application, the volume mass ratio of the solvent to the compound of formula I is 1 ml / g, 5 ml / g, 10 ml / g, 15 ml / g, 20 ml / g, 25 ml / g, 30 ml / g, 35 ml / g, 40 ml / g, 45 ml / g, 50 ml / g, 55 ml / g, 60 ml / g, 65 ml / g, 70 ml / g, 75 ml / g, 80 ml / g, 85 ml / g, 90 ml / g, 100 ml / g or a range formed by any proportion.
[0050] In some schemes of the present application, in the preparation method of the above-mentioned Type II crystal, the volume mass ratio of acetone to the compound of formula I is 1 to 50 ml / g; in some embodiments of the present application, the volume mass ratio of acetone to the compound of formula I is 1 ml / g, 5 ml / g, 10 ml / g, 15 ml / g, 20 ml / g, 25 ml / g, 30 ml / g, 35 ml / g, 40 ml / g, 45 ml / g, 50 ml / g or a range formed by any ratio; in some embodiments of the present application, the volume mass ratio of acetone to the compound of formula I is 5 to 40 ml / g or 10 to 30 ml / g; in some embodiments of the present application, the volume mass ratio of acetone to the compound of formula I is 20 ml / g.
[0051] In some schemes of the present application, in the preparation method of the above-mentioned type II crystal, the volume ratio of acetone to water is 1:0.5 to 1:5; in some embodiments of the present application, the volume ratio of acetone to water is 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5 or a range formed by any ratio; in some embodiments of the present application, the volume ratio of acetone to water is 1:0.5 to 1:2; in some embodiments of the present application, the volume ratio of acetone to water is 1:1.25.
[0052] In some embodiments, in the method for preparing the above-mentioned type II crystal, after the solid is precipitated, the solid can be separated by filtration.
[0053] In some embodiments of the present application, the method for preparing the above-mentioned type II crystal is to add the above-mentioned compound of formula I into a solvent, stir to dissolve, and optionally heat the solution to dissolve.
[0054] In some embodiments of the present application, the method for preparing the above-mentioned type II crystal optionally includes a process of cooling to room temperature and / or cooling and crystallizing in an ice-water bath, and / or optionally adding water to allow crystallization.
[0055] In some specific embodiments, the method for preparing the above-mentioned Type I crystal or Type II crystal further comprises drying the separated solid, for example, drying at 30-90°C; or drying at 50-60°C.
[0056] In this application, XRPD was detected by Bruker D8 ADVANCE X-ray powder diffractometer, light tube: Cu, kα Light tube voltage: 40kV, light tube current: 40mA; divergence slit: 0.618mm; scanning range: 3-60deg; step diameter: 0.02deg; step length: 0.1 second.
[0057] In the present application, DSC was detected using a Mettler DSC 1 differential scanning calorimeter, with a temperature range of 50-300° C. and a heating rate of 10.00 K / min.
[0058] On the other hand, the present application provides a crystalline composition, wherein the crystals of the compound of formula I described in the present application account for more than 50% of the weight of the crystalline composition, preferably more than 80%, more preferably more than 90%, and most preferably more than 95%.
[0059] On the other hand, the present application provides a crystalline composition comprising the above-mentioned Type I crystals and / or Type II crystals, wherein the Type I crystals and / or Type II crystals account for more than 50% of the weight of the crystalline composition, preferably more than 80%, more preferably more than 90%, and most preferably more than 95%.
[0060] In another aspect, the present application provides a pharmaceutical composition, which contains a therapeutically effective amount of a crystal of a compound of formula I described in the present application, or a crystal composition thereof. The pharmaceutical composition of the present application may contain or not contain a pharmaceutically acceptable excipient. In addition, the pharmaceutical composition of the present application may further include one or more other therapeutic agents.
[0061] On the other hand, the present application also provides the use of the crystal of the compound of formula I described in the present application, its crystalline composition, or its pharmaceutical composition in the preparation of drugs for preventing or treating diseases that benefit from the inhibition of capsid protein assembly.
[0062] On the other hand, the present application also provides the use of the crystal of the compound of formula I described in the present application, its crystal composition, or its pharmaceutical composition in the preparation of a drug for preventing or treating hepatitis B virus infection.
[0063] On the other hand, the present application also provides the use of the crystal of the compound of formula I described in the present application, its crystalline composition, or its pharmaceutical composition in preventing or treating diseases that benefit from the inhibition of capsid protein assembly.
[0064] On the other hand, the present application also provides a method for preventing or treating a disease that benefits from the inhibition of capsid protein assembly, comprising administering a therapeutically effective amount of a crystal of the compound of formula I described in the present application, a crystalline composition thereof, or a pharmaceutical composition thereof to a mammal, preferably a human, in need of such treatment or prevention.
[0065] On the other hand, the present application also provides crystals of the compound of formula I described in the present application, crystal compositions thereof, or pharmaceutical compositions thereof for preventing or treating diseases that benefit from the inhibition of capsid protein assembly.
[0066] As used in this application, the crystals of the compound of formula I described in this application are selected from the crystals of the compound of formula I, type I crystals of the compound of formula I, type II crystals of the compound of formula I, and a mixture of type I crystals and type II crystals of the compound of formula I.
[0067] In some embodiments of the present application, the disease that benefits from the inhibition of capsid protein assembly refers to a disease caused by hepatitis B virus (HBV) infection.
[0068] In some embodiments of the present application, the disease that benefits from the inhibition of capsid protein assembly refers to a liver disease caused by hepatitis B virus (HBV) infection.
[0069] In some embodiments of the present application, the prevention or treatment of diseases that benefit from the inhibition of capsid protein assembly refers to controlling, reducing or eliminating HBV to prevent, alleviate or cure liver diseases in infected patients.
[0070] Definition and Description
[0071] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.
[0072] It should be noted that in the powder X-ray diffraction spectrum, the position of the peak or the relative intensity of the peak may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, there may be an error in the position of the peak, and the measurement error of the 2θ value may be ±0.2°. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.
[0073] It should be noted that for the same crystal form, the position of the endothermic peak of DSC may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the position of the endothermic peak may have an error, which may be ±5°C or ±3°C. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.
[0074] The word “comprise” or “comprises” and its English variants such as comprises or comprising should be understood as having an open and non-exclusive meaning, ie, “including but not limited to”.
[0075] "Pharmaceutically acceptable excipients" refer to inert substances that are administered together with active ingredients and are beneficial to the administration of active ingredients, including but not limited to any glidants, sweeteners, diluents, preservatives, dyes / colorants, flavor enhancers, surfactants, wetting agents, dispersants, disintegrants, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers that are acceptable for humans or animals (e.g., livestock) and approved by the State Food and Drug Administration. Non-limiting examples of the excipients include calcium carbonate, calcium phosphate, various sugars and various types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycol.
[0076] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present application or their salts and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.
[0077] The pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.
[0078] Typical routes of administration of the crystals described herein or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.
[0079] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, sugar-coated pill making methods, grinding methods, emulsification methods, freeze-drying methods, etc.
[0080] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be prepared by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions, etc., for oral administration to patients.
[0081] The therapeutic dose of the compounds of the present application may be determined, for example, based on the specific purpose of the treatment, the method of administering the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds of the present application in the pharmaceutical composition may not be fixed, depending on a variety of factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. The term "treatment" means administering the compounds or formulations described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:
[0082] (i) inhibiting a disease or disease state, i.e. arresting its development;
[0083] (ii) ameliorating a disease or condition, even if causing regression of the disease or condition.
[0084] The term "prevention" means administering the compounds or formulations described herein to prevent a disease or one or more symptoms associated with the disease, and includes preventing a disease or disease state from occurring in a mammal, particularly when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state.
[0085] With respect to a drug or pharmacologically active agent, the term "therapeutically effective amount" refers to a sufficient amount of the drug or agent that is non-toxic but can achieve the desired effect. The determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.
[0086] The therapeutically effective amount of the crystals described herein is from about 0.0001 to 20 mg / Kg body weight / day, such as from 0.001 to 10 mg / Kg body weight / day.
[0087] The dosage frequency of the crystals described herein is determined by the needs of the individual patient, for example, once or twice a day, or more times a day. Administration can be intermittent, for example, wherein during a period of several days, the patient receives a daily dose of the crystals, and then during a period of several days or more days, the patient does not receive a daily dose of the crystals.
[0088] All solvents used in this application were commercially available and used without further purification.
[0089] The following abbreviations are used in this application: DMF represents N,N-dimethylformamide; PE represents petroleum ether; EA represents ethyl acetate; DMSO represents dimethyl sulfoxide; THF represents tetrahydrofuran; DCM represents dichloromethane; HATU represents 2-(7-benzotriazole oxide)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; DIPEA represents N,N-diisopropylethylamine.
[0090] Technical Effects
[0091] The crystals of the present application have good pharmacological activity and good stability under high humidity, high temperature or light, which proves their good pharmaceutical properties and high drug development prospects. DETAILED DESCRIPTION
[0092] The present application is described in detail below by way of examples, but this does not mean any adverse limitation to the present application. The present application has been described in detail herein, and its specific embodiments are also disclosed therein. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present application without departing from the spirit and scope of the present application.
[0093] Example 1 Preparation of Compounds of Formula I
[0094]
[0095] Step A: Under nitrogen protection, DMF (100 mL), ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate (8.0 g), and methyl iodide (8.15 g) were added to a 500 mL single-mouth bottle. Under ice bath, sodium hydride (2.87 g) was added in batches. After the addition, the mixture was transferred to room temperature for reaction for 2.5 h. After the reaction was completed, it was slowly poured into 400 mL of ice water for quenching, and extracted with ethyl acetate (2*300 mL). The organic layers were combined, washed with saturated sodium chloride aqueous solution, and the organic phase was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the crude product was separated by silica gel column chromatography (PE: EA = 20: 1) to obtain ethyl 1,2,4-trimethyl-1H-pyrrole-3-carboxylate (4.87 g). 1 H-NMR (500MHz, DMSO-d6): δ6.44 (s, 1H), 4.15 (q, J=7.5Hz, 2H), 3.44 (s, 3H), 2.39 (s, 3H), 2.09 (s, 3H), 1.25 (t, J=7.0Hz, 3H). 13 C-NMR (125MHz, DMSO-d6): δ165.63, 136.13, 120.78, 118.91, 110.56, 58.76, 33.58, 14.85, 12.93, 11.60.MS (ESI+, [M+H] + )m / z:182.3.
[0096] Step B: In a 500mL three-necked flask, under nitrogen protection, THF (150mL), 1,2,4-trimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (15.0g), 5-amino-2-fluorobenzonitrile (14.08g) were added, and bis(trimethylsilyl)amide lithium (27.7g, 166mL THF solution) was slowly added dropwise under ice bath, and the reaction was carried out at room temperature for 16.0h. After the reaction was completed, it was slowly poured into 500mL ice water for quenching, extracted with ethyl acetate (2*400mL), the organic layers were combined, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The crude product was separated by silica gel column chromatography (PE: EA = 1: 1) to obtain N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxamide (6.73g). 1 H-NMR (500MHz, DMSO-d6): δ9.64 (s, 1H), 8.18 (t, J=3.5Hz, 1H), 7.93-7.96 (m, 1 H), 7.48 (t, J=9.0Hz, 1H), 6.49 (s, 1H), 3.47 (s, 3H), 2.30 (s, 3H), 2.10 (s, 3H). 13 C-NMR (125MHz, DMSO-d6): δ165.51, 159.30, 157.15, 137.56, 131.76, 126.97, 123.33, 120.33, 117.39, 116.77, 114.59, 100.19, 33.53, 11.63.MS (ESI-, [MH] - )m / z:270.2.
[0097] Step C: Under nitrogen protection, DCM (240 mL), (N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxamide (5.0 g), and ethyl chlorooxalate (7.55 g) were added to a 500 mL single-mouth bottle. Aluminum chloride (12.29 g) was added in batches under an ice bath. After the addition, the mixture was transferred to room temperature and reacted for 15.0 h. After the reaction was completed, it was slowly poured into 300 mL of ice water to quench, and DCM (2*300 mL ) extraction, combined organic layers, washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, the filtrate was evaporated under reduced pressure to remove the solvent, ethyl acetate (45 mL) was added to the crude product, slurried at room temperature for 1.0 h, filtered, and the filter cake was dried in vacuo to obtain ethyl 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetate (4.25 g). MS (ESI-, [MH] - )m / z:370.2.
[0098] Step D: In an ice bath, add methanol (30 mL), ethyl 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetate (4.00 g), and a solution of sodium hydroxide (0.862 g) in water (30 mL) to a 100 mL single-necked bottle. After the addition is complete, transfer the mixture to room temperature and react for 2.0 h. Water (200 mL) and DCM (150 mL) were added to the reaction solution, the layers were separated, the organic layer was discarded, the aqueous layer was adjusted to pH 2 with concentrated hydrochloric acid, extracted with ethyl acetate (2*150 mL), the organic layers were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure to remove the solvent to give 2-(4-(3-cyano-4-fluorophenyl)carbamoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (3.25 g). 1 H-NMR (500MHz, DMSO-d6): δ10.32 (s, 1H), 8.19-8.21 (m, 1H), 7.93-7.97 (m, 1H), 7.52 (t, J=9.0Hz, 1H), 3.81 (s, 3H), 2.36 (s, 3H), 2.27 (s, 3H). 13 C-NMR (125MHz, DMSO-d6): δ178.85, 167.79, 163.98, 159.67, 157.66, 141.31, 136. 80, 130.95, 127.26, 123.84, 117.60, 114.43, 100.41, 60.21, 33.73, 21.22, 14.55.
[0099] Step E: To a 50 mL single-necked bottle, add DMF (3.0 mL), 2-(4-(3-cyano-4-fluorophenyl)carbamoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (100 mg), HATU (138 mg), DIPEA (83 mg), and then add (S)-1,1,1-trifluoroisopropylamine hydrochloride (56 mg), and stir at room temperature for 2.5 h. Water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2*50 mL). The organic layers were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The crude product was separated by silica gel column chromatography (PE:EA=1:1) to give (S)-N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxamide (54 mg). 1H-NMR (500MHz, DMSO-d6): δ10.31 (s, 1H), 9.38 (d, J=9.0Hz, 1H), 8.19-8.21 (m, 1H), 7.93-7.97 (m, 1H), 7.51 (t, J=9.5Hz, 1H), 4.68-4.75 (m, 1H), 3.79 (s, 3H), 2.36 (s, 3H), 2.21 (s, 3H), 1.31 (d, J=7.0Hz, 3H). 13 C-NMR (125MHz, DMSO-d6): δ180.80, 167.24, 164.08, 159.66, 157.65, 140.92, 136.82, 130.81, 127 .31, 125.02, 123.81, 120.71, 117.58, 114.44, 100.40, 46.04, 33.66, 13.75, 11.57.MS (ESI-, [MH] - )m / z:437.3.
[0100] Example 2 Preparation of Type I Crystals of Compound I
[0101] 100 g of the compound of formula I was added to 500 mL of anhydrous methanol for recrystallization at room temperature. A large amount of white solid was precipitated. The filter cake was filtered, rinsed with anhydrous methanol, and dried at 50° C. for 8 h to obtain 79 g of off-white type I crystalline solid of the compound of formula I. The sample was tested by XRPD. Figure 1 As shown, DSC detection Figure 2 shown.
[0102] Example 3 Preparation of Type I Crystals of Compound I
[0103] At room temperature, 400 mg of the compound of formula I was added to 5 mL of acetonitrile and stirred for 20 min to dissolve. 25 mL of purified water was added dropwise, and a large amount of white solid precipitated. The filter cake was filtered and dried at 60° C. for 6 h to obtain 303 mg of off-white type I crystalline solid of the compound of formula I.
[0104] Example 4 Preparation of Type II Crystals of Formula I Compound
[0105] At room temperature, 10 g of the compound of formula I was added to 200 mL of acetone and stirred to dissolve. 250 mL of purified water was slowly added dropwise. A large amount of white solid precipitated. The filter cake was filtered and air-dried at 60° C. for 7 h to obtain 7.2 g of off-white type II crystalline solid of the compound of formula I. The sample was tested by XRPD. Figure 3 As shown, DSC detection Figure 4 shown.
[0106] Experimental Example 1 Crystallization Stability Experiment
[0107] 1.1 Sample preparation
[0108] Weigh 500 mg of each of the Type I crystal of the compound of formula I prepared in Example 2 and the Type II crystal of the compound of formula I prepared in Example 4, place them in dry and clean weighing bottles, and spread them into a thin layer as test samples. Place the samples under the test conditions of influencing factors (40°C, 60°C, 75% RH, 92.5% RH, high temperature and high humidity (40°C, 75% RH)), and the samples are completely exposed. Take samples for analysis at 10 days and 30 days. Light (visible light 1200000Lux·hr, ultraviolet 216W·hr / m 2 ) conditions are fully exposed to room temperature.
[0109] 1.2 Instruments and analytical methods
[0110] The chromatographic column used was an Agilent AdvanceBio Peptide C18 column (4.6 mm×150 mm, 3.5 μm).
[0111] The moisture content was measured using a Mettler V20 moisture meter.
[0112] 1.3 Preparation of sample solution
[0113] About 10 mg of the sample was taken out and dissolved in an appropriate amount of diluent acetonitrile-water (70:30) to determine the concentration of the related substance.
[0114] Table 3-1 Stability test results of Form I
[0115]
[0116] a Related substances refer to total impurities.
[0117] The results in Table 3-1 show that the related substances and moisture of Form I remain stable under the above-mentioned multiple inspection items, proving that the crystal form has good high humidity, high temperature or light stability.
[0118] Table 3-2 Stability test results of Form II
[0119]
[0120] b Related substances refer to total impurities.
[0121] The results in Table 3-2 show that the related substances and moisture of Form II remain stable under the above-mentioned multiple inspection items, proving that the crystal form has good high humidity, high temperature or light stability.
[0122] Experimental Example 2. In vitro activity study
[0123] 2.1 In vitro HBV DNA inhibitory activity
[0124] Take a bottle of HepG2.2.15 (Wuhan Institute of Virology, Chinese Academy of Sciences) or HepAD38 cells in good exponential growth phase, add 5mL PBS to wash once, and add 3mL trypsin. Digest at room temperature for 5min, discard 2mL trypsin and put it in the cell culture incubator for digestion for 10min, take it out and observe it under the microscope (whether it is a single round, no adhesion between cells), and add 10mL complete medium to stop digestion. After blowing into a single cell suspension, take 10μL of cell suspension and count it with a cell counter, dilute it with complete medium, and adjust the cell density to 1*10 5 Use a spray gun to inoculate on a 24-well plate (the 24-well plate was pre-coated with 50 μg / mL Collagen I solution), 1 mL / well, and place in a constant temperature CO2 incubator for 48 hours.
[0125] The DMSO-dissolved compound was diluted with complete medium, 2-fold gradient, a total of 10 concentrations, and the compound was added. Fresh medium containing the compound was replaced every 72h, and the cells were treated with the compound for 6 days. After the supernatant was removed, 300 μL of lysis solution (10mM Tris-HCl, 1mM EDTA, 1% NP-40) was added to each well, and the cells were placed at room temperature for 10 minutes to lyse, and DNA was extracted. The HBV DNA in the intracellular viral capsid was determined by real-time fluorescence quantitative PCR, and the inhibition rate was calculated according to the Ct value, and the EC50 value was calculated by the four-parameter method. The results are shown in Tables 4 and 5.
[0126] Table 4 Results of the anti-HBV activity experiment in HepAD38 cells
[0127] Compound EC50 Compounds of formula I EC50≤10nM
[0128] Table 5 Experimental results of anti-HBV activity in HepG2.2.15 cells
[0129] Compound EC50 Compounds of formula I EC50≤10nM
[0130] 2.2 In vitro cytotoxicity
[0131] Take a bottle of HepG2.2.15 (Wuhan Institute of Virology, Chinese Academy of Sciences) or HepAD38 cells in good exponential growth phase, wash once with 5mL PBS, and add 2mL trypsin. Put it in a cell culture incubator for digestion, take it out from time to time and observe it under a microscope. When the cells just fall off, discard 1mL of trypsin, leaving only the residual liquid, put it in a 37℃ incubator for digestion for 8-15min, take it out and observe the cells under a microscope (whether they are single round and there is no adhesion between cells), and add 5mL MEM culture medium to resuspend the cells. Use a cell counter to count, dilute with complete culture medium, and adjust the cell density to 2*10 5 / mL. Use a spray gun to inoculate on a 96-well plate (the 96-well plate was pre-coated with 50μg / mL Collagen I solution), 100μL / well, and culture in a constant temperature CO2 incubator for 24h. After drug treatment, replace the fresh medium containing the compound every 3 days, add a medium containing 0.5% DMSO without drugs to the control well, and set up a control well of ordinary culture medium. After 6 days of drug treatment, add CCK-8, 10μL / well, and detect its absorbance at 450nm with a microplate reader after 1-2h, calculate the inhibition rate, and calculate CC50. The results are shown in Table 6.
[0132] Table 6
[0133] cell CC50(μM) Compound HepAD38 >100 Compounds of formula I HepG2.2.15 >100 Compounds of formula I
[0134] 2.3 CYP450 enzyme induction studies
[0135] The final 500μL incubation system contains 50μL liver microsomes (protein concentration: 0.2mg / mL, Corning), 1μL mixed CYP450 specific substrates (CYP1A2, CYP 2B6, CYP 2C9, CYP2C19, CYP 2D6, CYP 3A4), 398μL PBS buffer (PH7.4), 1μL specific positive inhibitor (positive control group) or test compound (acetonitrile), 50μL NADPH + MgCl2. Each CYP450 subtype is made into 2 copies, each with 0.5mL. Prepare a total volume of 450μL of substrate and enzyme mixed solution and NADPH in each tube, pre-incubate at 37℃ for 5min, then add 50μL NADPH + MgCl2 mixed solution for reaction, take out 50μL at 30min and terminate the reaction with 300μL of ice acetonitrile containing internal standard. In addition, two blank groups of 500 μL each were prepared in parallel without adding NADPH as negative control groups.
[0136] Sample pretreatment: 50 μL of incubated sample, add 300 μL of glacial acetonitrile containing internal standard to precipitate, vortex shake for 5 minutes, centrifuge (12000 rpm, 4°C) for 10 minutes. Pipette 75 μL of supernatant, add 75 μL of ultrapure water, dilute and mix, and inject 1 μL for analysis. The results are shown in Table 7.
[0137] Table 7
[0138]
[0139] 2.4 Plasma protein binding test
[0140] Preparation of plasma samples: 495 μL of blank plasma of the corresponding species (mouse, rat, dog, monkey and human) was drawn respectively, and 5 μL of the corresponding test compound solution or positive control was added to obtain plasma sample solutions, so that the compound plasma drug concentrations were 1 μM and 10 μM, respectively (prepared in acetonitrile).
[0141] The pretreated dialysis membrane was placed in a high-throughput equilibrium dialysis device, and 100 μL of plasma sample solution and PBS buffer were drawn and added to both sides of the dialysis membrane (sample side and buffer side) (n=3), respectively. After the equilibrium device was sealed with a film, it was incubated at 37°C overnight (100 rpm). After the dialysis equilibrium was reached, 50 μL of sample was drawn from the sample side and the buffer side, respectively, and the reaction was terminated with ice-cold acetonitrile containing an internal standard.
[0142] Sample pretreatment: 50 μL plasma side sample, add 450 μL glacial acetonitrile containing internal standard to precipitate, vortex and shake for 5 minutes, centrifuge (12000rpm, 4℃) for 10 minutes. Take 75 μL of supernatant, add 75 μL ultrapure water to dilute and mix, and inject 1 μL for analysis; 50 μL PBS side sample, add 250 μL glacial acetonitrile containing internal standard to precipitate, vortex and shake for 5 minutes, centrifuge (12000rpm, 4℃) for 10 minutes. Take 75 μL of supernatant, add 75 μL ultrapure water to dilute and mix, and inject 2 μL for analysis. The results are shown in Table 8.
[0143] Table 8
[0144]
[0145] Experimental Example 3 In vitro liver microsome stability
[0146] The final 300μL incubation system contains 30μL liver microsomes (protein concentration: 0.15mg / mL), 30μL NADPH+MgCl2, 3μL substrate (prepared in acetonitrile), and 237μL PBS buffer. Two copies of each species are made, each copy is 0.3mL. Prepare a total volume of 270μL of substrate and enzyme mixed solution in each tube, pre-incubate with NADPH at 37℃ for 5min, add 30μL NADPH+MgCl2 mixed solution to react, take out 50μL at 0, 10, 30, and 60min, and terminate the reaction with 300μL of ice acetonitrile containing internal standard.
[0147] Sample pretreatment: 50 μL of incubated sample was added with 300 μL of glacial acetonitrile containing internal standard diazepam for precipitation, vortexed for 5 mm, and centrifuged (12000 rpm, 4°C) for 10 min. 75 μL of supernatant was taken into a 96-well plate, diluted and mixed with 75 μL of ultrapure water, and 0.5 μL was injected for LC-MS / MS analysis. The results are shown in Table 9.
[0148] Table 9 In vitro liver microsome stability
[0149]
[0150] Experimental Example 4 Solubility in PBS buffer at pH 7.4
[0151] The final 1000μL system contained 990μL of pH7.4 PBS buffer and 10μL of the test compound (prepared in acetonitrile). After standing at 25℃ for 16h, centrifuge (12000rpm, room temperature) for 10min, take out 20μL of the supernatant, and terminate the reaction with 400μL of acetonitrile containing internal standard (diazepam 20ng / mL). Take 30μL of the supernatant, add 150μL of 50% acetonitrile water to dilute and mix, and inject 0.5μL for analysis. The results are shown in Table 10.
[0152] Table 10
[0153] Compound Solubility (μM) Compounds of formula I 8.1
[0154] Experimental Example 5: In vivo animal efficacy
[0155] 5.1 Evaluation of antiviral effects in AAV mouse model
[0156] 6-8 week old male C57BL / 6 mice (Shanghai Lingchang Biotechnology Co., Ltd.) were selected and 1×10 11vg dose, and rAAV8-1.3HBV virus (Beijing Acanthopanax, adr subtype) was injected into C57BL / 6 mice through the tail vein. Blood was collected from the mouse orbits at 2 and 4 weeks after virus injection, and serum was separated to determine the expression levels of HBeAg and HBsAg in the serum and the number of HBV DNA copies to determine whether the model was successfully constructed. Combined with the quantitative detection results of serological HBeAg, HBsAg and HBV DNA, the selected mice had HBV DNA expression levels greater than 1×10 4 IU / mL, HBeAg greater than 1×10 3 NCU / mL and HBsAg greater than 1×10 3 ng / mL. The mice were divided into a blank control group, a solvent control group, and a test group. Each group of mice was given the drug by gavage for 2-3 weeks, once a day. During the experiment, blood was collected from the eye sockets every other week, serum was separated, and the DNA content was detected by fluorescent quantitative PCR. The results are shown in Table 11.
[0157] Table 11 Decrease level of HBV DNA in serum (log10) (administered for 24 days, dose 30 mpk)
[0158] Compound Day 7 Day 14 Day 21 Day 28 Compounds of formula I 2.42 3.46 5.08 2.48
[0159] 5.2 Evaluation of antiviral efficacy in HDI mouse model
[0160] 6-8 week old male C57BL / 6 mice (Shanghai Lingchang Biotechnology Co., Ltd.) were taken, and the purified recombinant plasmid pHBV1.3 (10 μg) was dissolved in PBS. The injection volume of each mouse was about 10% of its body weight, and it was injected into the mouse through the tail vein within 3-8 seconds. 24 hours after the injection of the plasmid, blood was collected from the orbit to detect serum HBV DNA, and the model mice with uniform serum DNA were selected for grouping, and a blank control group, a solvent control group, and a test group were set up. Each group of mice was given the drug by gavage for 6 consecutive days, once a day, at a dose of 30 mg / kg. The mouse serum was taken on the 1st, 3rd, 5th, and 7th day after the injection, and the mice were killed on the 7th day to take liver tissue samples. The number of HBV DNA copies in the mouse serum and liver was detected by fluorescent quantitative PCR. The results are shown in Table 12.
[0161] Table 12
[0162] Compound The decrease level of HBV DNA in serum on day 5 (log10) Compounds of formula I 2.17
[0163] Experimental Example 6 In vivo drug metabolism kinetics
[0164] 6.1 Pharmacokinetic (PK) study in rats
[0165] SD rats (Shanghai Xipu-Bikai) weighing 180-220 g were randomly divided into groups after acclimation for 3-5 days, with 3 rats in each group, and were intragastrically administered with a series of compounds at a dose of 20 mg / kg.
[0166] The test animals (SD rats) were fasted for 12 h before administration and given food 4 h after administration. They were allowed to drink water freely before, during and after the experiment.
[0167] After administration, about 0.2 mL of blood was collected from the eye socket at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 24 h, 30 h, and 48 h. After anticoagulation with EDTA-K2, the blood was centrifuged at 4 ° C and 4000 rpm for 10 min within 30 min to separate the plasma. After all the plasma was collected, it was immediately stored at -20 ° C for testing.
[0168] 50 μL of the plasma sample to be tested and the standard curve sample were drawn, 500 μL of acetonitrile solution containing internal standard (diazepam 20 mg / mL) was added, oscillated and mixed for 5 minutes, centrifuged at 12000 rpm for 10 minutes, 75 μL of the supernatant was taken, 75 μL of ultrapure water was added to dilute, mixed, and 1 μL was drawn for LC / MS / MS determination. The results are shown in Table 13.
[0169] Table 13
[0170]
[0171] NA means not detected.
[0172] 6.2 Pharmacokinetic (PK) study in beagle dogs
[0173] Beagle dogs, weighing 9-11 kg, were randomly divided into two groups, 3 in each group, and the compound of formula I was gavaged at a dose of 5 mg / kg.
[0174] The test animals (beagle dogs) were fasted for 12 h before administration and given food 4 h after administration. They were allowed to drink water freely before, during and after the experiment.
[0175] After intragastric administration, about 0.5 mL of whole blood was collected from the left forelimb vein at 0min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 24h, 48h, and 72h, and placed in a vacuum blood collection tube anticoagulated with EDTA-K2. The blood was centrifuged at 4°C and 4000rpm for 10min within 30min to separate the plasma. After all the plasma was collected, it was immediately stored at -20°C for testing. After all the plasma was collected, it was immediately stored at -20°C for testing.
[0176] 50 μL of the plasma sample to be tested and the standard curve sample were drawn, 500 μL of acetonitrile solution containing internal standard (diazepam 20 mg / mL) was added, oscillated and mixed for 5 minutes, centrifuged at 12000 rpm for 10 minutes, 75 μL of the supernatant was taken, 75 μL of ultrapure water was added to dilute, mixed, and 1 μL was drawn for LC / MS / MS determination. The results are shown in Table 14.
[0177] Table 14
[0178] Compound Compounds of formula I Administration and dosage PO 5 mg / kg <![CDATA[T max (h)]]> 1.67 <![CDATA[C max (ng / mL)]]> 1282 <![CDATA[AUC (0-72h) (ng*h / mL)]]> 61881 <![CDATA[AUC (0-∞) (ng*h / mL)]]> 162075 T1 / 2(h) 105.2 MRT(0-t)(h) 32.9 .
Claims
1. A crystal of the compound of formula I, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 16.47±0.20°, 18.11±0.20°, 24.48±0.20° and 26.79±0.20° 2. The crystal of the compound of formula I according to claim 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 12.72±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 19.79±0.20°, 24.48±0.20° and 26.79±0.20°.
3. The crystal of the compound of formula (I) according to claim 1, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 10.44±0.20°, 12.72±0.20°, 15.06±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 19.79±0.20°, 20.46±0.20°, 24.48±0.20°, 26.79±0.20°, and 31.46±0.20°.
4. The crystal of the compound of formula (I) as claimed in claim 1, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.21±0.20°, 9.68±0.20°, 10.44±0.20°, 12.72±0.20°, 15.06±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 19.79±0.20°, 20.46±0.20°, 24.48±0.20°, 26.02±0.20°, 26.79±0.20°, 27.67±0.20° and 31.46±0.20°.
5. The crystal of the compound of formula I according to claim 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.86±0.20°, 9.21±0.20°, 9.68±0.20°, 10.44±0.20°, 12.47±0.20°, 12.72±0.20°, 15.06±0.20°, 15.71±0.20°, 16.47±0.20°, 18.11±0.20°, 18.74±0.2 0°, 19.19±0.20°, 19.79±0.20°, 20.46±0.20°, 20.94±0.20°, 21.65±0.20°, 21.96±0.20°, 23.12±0.20°, 24.48±0.20°, 26.02±0.20°, 26.79±0.20°, 27.67±0.20°, 29.36±0.20°, 31.46±0.20° and 34.17±0.20°.
6. The crystal of the compound of formula (I) as claimed in claim 1, whose XRPD pattern is shown in Figure 1.
7. The crystal of the compound of formula I as claimed in claim 1, wherein the DSC curve thereof has an endothermic peak at 231.26±5°C.
8. A crystal of the compound of formula I, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 14.09±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20° and 22.91±0.2° 9. The crystal of the compound of formula I as claimed in claim 8, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.45±0.20°, 13.35±0.20°, 14.09±0.20°, 14.90±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20°, 19.64±0.20° and 22.91±0.2°.
10. The crystal of the compound of formula (I) according to claim 8, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.45±0.20°, 11.15±0.20°, 13.35±0.20°, 14.09±0.20°, 14.90±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20°, 19.64±0.20°, 20.97±0.20°, 22.91±0.2°, 23.68±0.20°, and 25.24±0.2°.
11. The crystal of the compound of formula (I) as claimed in claim 8, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.45±0.20°, 11.15±0.20°, 13.35±0.20°, 14.09±0.20°, 14.90±0.20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20°, 19.64±0.20°, 20.25±0.20°, 20.97±0.20°, 21.42±0.20°, 22.91±0.2°, 23.68±0.20°, 25.24±0.2°, 27.72±0.2° and 30.00±0.2°.
12. The crystal of the compound of formula I according to claim 8, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.74±0.20°, 7.94±0.20°, 8.45±0.20°, 9.40±0.20°, 9.91±0.20°, 11.15±0.20°, 13.35±0.20°, 14.09±0.20°, 14.90±0. 20°, 15.81±0.20°, 17.40±0.20°, 18.81±0.20°, 19.64±0.20°, 20.25±0.20°, 20.97±0.20°, 21.42±0.20°, 22.91±0.2°, 23.68±0.20°, 25.24±0.2°, 27.72±0.2°, and 30.00±0.2°.
13. The crystal of the compound of formula (I) as claimed in claim 8, whose XRPD pattern is shown in Figure 3.
14. The crystal of the compound of formula I as claimed in claim 8, wherein the DSC curve thereof has an endothermic peak at 225.05±5°C.
15. A crystalline composition comprising crystals of the compound of formula I according to any one of claims 1 to 14, wherein the crystals account for more than 50% of the weight of the crystalline composition.
16. The crystalline composition according to claim 15, comprising crystals of the compound of formula I according to any one of claims 1 to 14, wherein the crystals account for more than 80% of the weight of the crystalline composition.
17. The crystalline composition according to claim 15, comprising crystals of the compound of formula I according to any one of claims 1 to 14, wherein the crystals account for more than 90% of the weight of the crystalline composition.
18. The crystalline composition according to claim 15, comprising crystals of the compound of formula I according to any one of claims 1 to 14, wherein the crystals account for more than 95% of the weight of the crystalline composition.
19. A pharmaceutical composition comprising a therapeutically effective amount of a crystal of a compound of formula I as claimed in any one of claims 1 to 14 or a crystalline composition as claimed in any one of claims 15 to 18.
20. Use of a crystal of a compound of formula I according to any one of claims 1 to 14, or a crystalline composition according to any one of claims 15 to 18, or a pharmaceutical composition according to claim 19 in the preparation of a medicament for preventing or treating a disease that benefits from inhibition of capsid protein assembly.
21. The use according to claim 20, wherein the disease that benefits from the inhibition of capsid protein assembly is a disease caused by hepatitis B virus infection.
Citation Information
Patent Citations
N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
WO2019185016A1
Hepatitis b capsid assembly modulators
WO2019241292A1
N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof
WO2020151252A1
